Susan Hsu, managing director of Taiwanese data-driven CRO StatPlus, speaks about the key trends impacting Taiwan’s clinical trial environment and goes on to share her views on the increasing attractiveness of the island. Hsu concludes by explaining the service provider’s strategic position within APAC and its unique strength as a globally active, local expert.
Many Taiwanese companies are too small to enter the global market on their own. In order to be able to attract international partners, more data and evidence is needed to prove the efficacy of their products
